🇬🇧 UNITED KINGDOM +44 (0)1472 493294 Direct john.paul@procxinc.com
Talk to an Engineer

INDUSTRY · PHARMACEUTICAL & LIFE SCIENCE

Pharmaceutical Processing Equipment & Integrated Life Science Manufacturing Systems

Engineered Around the Product. Designed Around the Process. Documented Around the Requirement.

Talk to Our Team → Explore Our Brands →

In pharmaceutical manufacturing, the machine is only one part of the equation.

A process may need to control:

And every one of those parameters can influence the quality of the material that moves to the next manufacturing step.

That is why Proc-X Manufacturing Group Inc. approaches pharmaceutical and life-science processing as an integrated engineering problem rather than a catalogue of standalone machines.

Our specialist technologies can support pharmaceutical applications involving:

ingredient handling → dosing → milling → blending → granulation → liquid processing → vacuum drying → particle conditioning → inspection → filling → packaging

under one connected engineering platform.

The objective is not simply to manufacture equipment.

It is to engineer the process around the material, critical process parameters and defined product-quality requirements.

Pharmaceutical Manufacturing Demands More

A pharmaceutical processor cannot evaluate equipment solely from vessel volume, motor power, litres per hour, or advertised throughput.

The questions are different.

Those questions determine the equipment.

Our internal pharmaceutical qualification framework explicitly begins with the material, process target, capacity, GMP/hygiene, containment/safety and automation/documentation requirements rather than equipment size alone.

One Connected Pharmaceutical Processing Platform

Proc-X connects specialist process technologies across the pharmaceutical manufacturing chain.

Proc-X then integrates the controls, process interfaces, documentation and project execution surrounding those technologies.

From Raw Material to Controlled Pharmaceutical Process

A pharmaceutical process may begin with materials arriving as:

Those materials may eventually become:

Between those two points, material properties can change dramatically.

Proc-X looks at the entire path.

Automated Pharmaceutical Ingredient Handling

AIS — Automated Ingredient Systems

Repeatability begins before the mixer.

A formulation cannot be more accurate than the ingredients introduced into it.

AIS can support automated handling and dosing architectures for:

Potential system functions include:

When Milligrams and Grams Matter

The smallest ingredient in the formulation may be the most critical.

Micro ingredient systems therefore require a different engineering philosophy than bulk ingredient handling.

Feeder geometry, load-cell resolution, vibration, refill strategy, product flow and dosing sequence all affect performance.

The objective is not simply to automate the addition.

The objective is to make the addition measurable, controlled and repeatable.

Pharmaceutical Milling & Particle Size Reduction

DP Mills

Particle size can influence pharmaceutical performance at nearly every downstream stage.

It may affect:

That is why DP approaches pharmaceutical milling as particle engineering rather than generic grinding.

Internal Proc-X training specifically positions DP milling for API and excipient applications where particle-size distribution is a release-critical or downstream-process variable.

Define PSD — Not “Fine Powder”

One of the most important pharmaceutical milling questions is:

What does “fine” actually mean?

A useful specification may require:

Proc-X’s internal pharmaceutical methodology explicitly calls for numerical PSD definition rather than relying on “mesh” or qualitative descriptions alone.

That matters because two powders with the same nominal average particle size may behave very differently downstream.

Air Classifier Mills for Pharmaceutical Powders

DP Air Classifier Mills combine mechanical impact milling with dynamic classification.

They can be attractive where pharmaceutical processing requires:

Because acceptable fines can leave the grinding zone while oversized particles are internally recycled, the process provides more particle-size control than conventional impact milling alone.

Jet Milling

Jet milling can be evaluated when the process requires:

The correct technology depends on the material and target PSD.

Pin Milling & Intermediate Fine Grinding

Pin mills can provide repeated high-speed impact for suitable friable powders.

They may be used for selected excipients, crystalline ingredients, pharmaceutical intermediates and dry powder applications where an ACM or jet mill is unnecessary.

Cryogenic Milling

Some pharmaceutical materials cannot be processed effectively at ambient temperature because they soften, smear, become elastic, degrade or lose stability as temperature rises.

Cryogenic conditioning can alter the mechanical behaviour of the product before milling.

The right technology is determined by the material—not simply the final micron target.

Trial Before Guarantee

Difficult pharmaceutical milling applications should be qualified with representative material whenever possible.

Our internal methodology specifically recommends representative trials before guaranteeing throughput plus PSD on difficult products, with temperature, dust, cleanability and process conditions considered as part of the sizing basis.

That reduces scale-up risk and creates a defensible performance basis.

Pharmaceutical Powder Mixing

QuantumX Mixing Technologies

Uniformity is central to pharmaceutical blending.

The formulation may contain materials with significant differences in particle size, density, concentration, shape, flowability and cohesiveness.

QuantumX offers several mixing geometries so the agitator can be selected around the product.

Potential platforms include:

API & Excipient Blending

For a pharmaceutical powder blend, the objective may be to achieve controlled distribution of an API throughout a much larger excipient mass.

The equipment must therefore be evaluated around factors including:

A homogeneous blend inside the mixer can still segregate if the discharge and transfer process are poorly engineered.

Proc-X therefore evaluates more than the agitator itself.

Gentle Pharmaceutical Blending

Some formulations require minimal particle damage.

Paddle, ribbon or selected conical configurations can provide controlled convective mixing while reducing unnecessary mechanical stress.

This may be valuable for:

High-Intensity Pharmaceutical Mixing

Other processes require more aggressive mixing.

Ploughshare or high-speed technologies may be appropriate where the process requires:

The correct mixer is selected around the process objective.

Wet Granulation

QuantumX High-Speed Mixer / Wet Granulator

Wet granulation combines multiple unit operations inside one process vessel.

A typical process may include:

dry powder charging → dry blending → binder addition → wet massing → granule development → discharge

QuantumX high-speed mixer/granulator technology is designed around rapid dry mixing, binder addition and controlled granule formation. Proc-X’s pharmaceutical training framework identifies batch size, formulation, binder system, endpoint, impeller/chopper requirements and downstream interface as key qualification variables.

Granulation Is About the Endpoint

The correct granulator cannot be selected from vessel size alone.

Important questions include:

The goal is not simply to create a wet mass.

It is to create a controlled intermediate suitable for the next manufacturing operation.

Binder Addition

Binder introduction can strongly influence granule structure.

Poor liquid distribution can create:

Spray geometry, flow rate, droplet size and mixing energy must therefore work together.

Integrated Granulation & Drying

Selected QuantumX platforms can combine granulation and vacuum drying inside one process system.

This can reduce:

Internal Proc-X technical material specifically includes high-speed granulator/dryer configurations as part of the pharmaceutical vacuum-processing portfolio.

Pharmaceutical Vacuum Mixing & Drying

QuantumX Vacuum Mixers & Dryers

Vacuum processing is one of the strongest Proc-X capabilities for pharmaceutical applications.

A QuantumX vacuum system can combine:

mixing + heating + cooling + deagglomeration + vacuum drying

within a single closed process vessel.

This can reduce product transfers and help control exposure.

Proc-X’s pharmaceutical portfolio includes vacuum ribbon, vacuum plough, vacuum paddle and high-speed granulator/dryer technologies, with pharmaceutical applications including API blending, wet granulation, vacuum drying, containment and controlled-atmosphere processing.

Why Vacuum Drying Matters in Pharmaceuticals

Vacuum lowers the boiling temperature of water and many solvents.

That can allow evaporation at reduced product temperature.

This may be important for:

Heat Transfer + Mass Transfer

Successful vacuum drying requires both.

Heat must enter the product.

Moisture or solvent must leave it.

The agitator continuously exposes new product to thermal surfaces while helping release vapour from the batch.

That is why mixer geometry is central to dryer performance.

Vacuum Ribbon Mixer & Dryer

A ribbon configuration may be appropriate for general pharmaceutical powder and granule drying where convective circulation and comparatively gentle processing are desired.

Vacuum Paddle Mixer & Dryer

Paddle configurations can provide effective product movement with controlled mechanical intensity.

They may be particularly attractive for fragile products, heat-sensitive granules, crystals and formulations where particle integrity is important.

Vacuum Ploughshare Mixer & Dryer

Ploughshare systems create substantially more dynamic material movement.

They can be considered for cohesive products, difficult drying behaviour, agglomerated materials, intensive deagglomeration or applications requiring higher surface renewal.

Vertical Conical Vacuum Processing

Vertical conical systems can provide gentle mixing, efficient gravity-assisted discharge and low product retention.

This type of geometry can be particularly attractive for high-value or sensitive pharmaceutical materials.

Residual Moisture Is a Process Endpoint

A pharmaceutical vacuum dryer should not be specified only by batch size and drying time.

The relevant variables can include:

Those are specifically identified in Proc-X’s internal pharmaceutical vacuum-dryer qualification methodology.

Solvent Removal & Recovery

Pharmaceutical intermediate processing may involve solvent-wet materials.

A vacuum system can be engineered with vapour filtration, condensers, receivers, vacuum pumps, nitrogen systems and solvent-recovery components.

The exact design depends on the solvent and process.

Solvent handling must be evaluated alongside:

Pharmaceutical Liquid Processing

EmulXion

Pharmaceutical manufacturing increasingly involves complex fluid systems.

Applications may include:

EmulXion provides liquid-processing technologies including:

High-Shear Processing

High-shear rotor-stator systems can support applications involving powder wetting, dispersion, deagglomeration, emulsification, active distribution and preparation of controlled premixes.

The appropriate shear level depends on the material.

Pharmaceutical High-Pressure Homogenization

EmulXion High-Pressure Homogenizers are specifically positioned for:

The technology pressurizes the fluid and forces it through precision homogenization geometry, creating combinations of turbulence, cavitation, hydraulic shear and impact.

These mechanisms can reduce particles and droplets into microscopic and potentially nanometre-scale ranges depending on the formulation.

Liposomal Processing

Liposomes and other advanced delivery systems require control of particle or vesicle size, distribution, formulation, temperature and process energy.

High-pressure homogenization can become part of a controlled development process for these systems.

Cell Disruption & Biotechnology

High-pressure homogenization can also be used for selected cell-disruption applications.

Biological material passes through an intense hydrodynamic environment where pressure change, cavitation, turbulence and shear can disrupt cellular structures.

This expands EmulXion beyond conventional pharmaceutical mixing into biotechnology and life-science processing.

Pharmaceutical Suspensions

Suspensions can present challenges including:

The process may require a combination of:

powder induction → high-shear dispersion → homogenization → deaeration → controlled holding

rather than one mixer alone.

Pharmaceutical Emulsions

Stable emulsions depend on more than mechanical energy.

They depend on phase ratio, emulsifier chemistry, viscosity, temperature, droplet size, process sequence and stabilization.

The homogenizer can create droplet size.

The formulation must maintain it.

Containment

For pharmaceutical processing, product containment may be as important as product throughput.

Potential requirements can include:

The correct design depends on the material and site requirements.

OEB and OEL

Potent compounds may require defined occupational exposure control.

Proc-X’s internal pharma qualification checklist specifically calls for confirmation of:

These requirements must be established with the customer’s EHS, engineering and quality teams before the equipment design is finalized.

Cleanability Is Part of the Process

Pharmaceutical equipment should not simply be stainless steel.

A cleanable system must consider:

The cleaning strategy may include manual cleaning, WIP, CIP, or an application-specific approach.

Cleaning Validation

Cleaning equipment and validating cleaning are not the same thing.

The machine can be designed to support cleanability.

The customer’s quality system establishes how cleaning effectiveness is demonstrated.

Our internal pharmaceutical framework therefore specifically asks for the intended validation strategy and swab access, rather than assuming one universal cleaning standard.

Material of Construction & Surface Finish

The appropriate metallurgy and product-contact finish must be selected around formulation, corrosion, cleaning chemistry, contamination risk and quality requirements.

Potential designs may include application-specific stainless steels and polished contact surfaces.

The final requirement must be established project-by-project.

CIP and SIP

Where applicable, process systems can be engineered around clean-in-place or sterilization-related requirements.

However, the exact CIP/SIP architecture must be based on:

These are not generic check-box options.

Automation & Pharmaceutical Process Control

A repeatable process requires repeatable controls.

Depending on the project, Proc-X equipment can incorporate:

Data Integrity & Electronic Records

Some regulated processes require electronic-record or electronic-signature functionality.

Proc-X has developed qualification documentation that references 21 CFR Part 11 and EU GMP Annex 11 when regulated electronic records or signatures are actually in scope.

That distinction matters.

Part 11 applicability must be confirmed project-by-project.

A generic PLC or HMI should never automatically be described as “Part 11 compliant” without defining the required software architecture, audit trail, user access, records and validation scope.

IQ / OQ / PQ Support

Proc-X and QuantumX have developed formal qualification documentation structures for projects requiring Installation Qualification, Operational Qualification and Performance Qualification support.

Our validation documentation framework can address elements such as:

The exact qualification package must be agreed for each project.

Qualification Is a Shared Responsibility

Pharmaceutical validation is not something the machine supplier performs independently of the customer.

The customer’s Quality, Engineering, Production, EHS, Validation and Laboratory teams all have defined responsibilities.

Proc-X qualification documentation explicitly distinguishes customer approval and execution responsibilities from supplier documentation and technical-support responsibilities.

That creates a more defensible validation model.

URS-Driven Engineering

For regulated projects, the User Requirements Specification should become a central engineering document.

The URS helps establish:

Proc-X’s own qualification structure identifies the final approved URS as the primary requirement source for project qualification.

FAT for Pharmaceutical Equipment

Factory Acceptance Testing can verify agreed equipment functions before shipment.

Depending on scope, FAT may include:

The agreed FAT protocol should reflect the actual project requirements.

SAT & Commissioning

After installation, site activities can confirm utilities, connections, installation, controls, integration and equipment operation under the customer’s facility conditions.

Commissioning provides the bridge between a delivered machine and a functioning production process.

Pharmaceutical Packaging & Filling

PreciXion Packaging & Filling

The process does not finish when the material leaves the mixer, dryer or homogenizer.

PreciXion provides downstream filling and packaging technologies for pharmaceutical and life-science products.

Potential applications include:

PreciXion’s platform includes application engineering, documentation packages, FAT/SAT, sanitary and washdown design and lifecycle support.

Powder Filling

Pharmaceutical powders may require:

The filling technology must reflect the powder’s density, flowability, potency, dust behaviour, target quantity and required accuracy.

Liquid & Semi-Solid Filling

Pharmaceutical liquids, suspensions, creams and gels may require:

Sachets, Pouches & Small-Format Packaging

PreciXion can support small-format packaging architectures for suitable powders, granules, liquids and other pharmaceutical products.

The line can integrate downstream verification and coding requirements.

Pharmaceutical Inspection

InspeX

Inspection can be incorporated into pharmaceutical lines for contamination control, weight verification, automated rejection and production-data support.

Depending on the product, systems may include conveyor metal detection, checkweighing, combination inspection or other application-specific technologies.

Protecting More Than the Finished Product

Inspection may also be placed earlier in the process to protect mills, extruders, pumps, homogenizers and other high-value equipment from metallic foreign material.

The correct inspection point is determined through process risk analysis.

Batch Processing and Continuous Processing

Proc-X technologies can support both philosophies.

Batch Processing

Appropriate where the process requires:

Continuous Processing

Appropriate where:

are central to the application.

The equipment architecture should follow the manufacturing strategy.

Reducing Material Transfers

Every transfer can introduce exposure, contamination risk, product loss, hold-up, cleaning requirements and operator intervention.

This is one reason integrated vacuum mixing and drying can be valuable.

Proc-X’s internal pharmaceutical training specifically identifies reduced transfers, reduced exposure and reduced handling as benefits of combining mixing and drying functions within one vessel.

High-Value Product Yield

In pharmaceutical manufacturing, a small amount of residual product can represent significant value.

System design can therefore consider:

Yield should be considered during equipment design—not after startup.

Heat-Sensitive APIs and Formulations

Temperature can influence degradation, potency, crystal form, solvent behaviour, viscosity and product stability.

Processing equipment may therefore require:

Hygroscopic Products

Materials that rapidly absorb moisture can create additional handling challenges.

The process may require:

This should be evaluated across the entire process path.

Controlled Atmosphere & Nitrogen

Selected pharmaceutical products may require inert or controlled-atmosphere operation.

Nitrogen can be incorporated for purposes such as:

Oxygen monitoring and process interlocks may be required depending on the application.

Solvents & Hazardous Processing

Processes involving solvents may require additional engineering around:

Proc-X qualification documentation includes ATEX hazardous-area scheduling, ignition-hazard review, grounding, zoning and certification where applicable.

Regulatory Requirements Must Be Defined — Not Assumed

This is a critical Proc-X position.

Pharmaceutical manufacturing spans many products, jurisdictions, quality systems, dosage forms and regulatory expectations.

A generic brochure cannot define which requirements apply to every project.

Our own internal pharmaceutical guidance explicitly states:

regulatory and validation requirements must be confirmed project-by-project and compliance should never be implied from a generic brochure.

That is how we intend to approach pharmaceutical engineering.

Pharmaceutical Process Development

Some applications cannot be responsibly specified from a datasheet.

They require development work.

Testing may be appropriate for:

The purpose is to turn assumptions into measurable engineering data.

From Vague Requirement to Defined Process

Consider the statement:

“We need a fine pharmaceutical powder.”

That is not yet an equipment specification.

A stronger engineering basis might become:

That transformation from vague requirement to measurable process basis is exactly how Proc-X trains its pharmaceutical project teams to approach technical opportunities.

Process Endpoints Matter

A pharmaceutical process should have a defined endpoint.

Depending on the operation, that may be:

When the endpoint is defined, the equipment can be engineered around achieving it.

Pharmaceutical Applications

Proc-X technologies can be evaluated for pharmaceutical and life-science processes including:

The correct process train is developed around the actual product.

Pharmaceutical Production Is a Chain of Critical Interfaces

A typical process may look like:

raw material receiving
↓
contained ingredient transfer
↓
precision weighing and dosing
↓
particle-size reduction
↓
powder blending
↓
binder addition
↓
wet granulation
↓
vacuum drying
↓
final milling / sizing
↓
inspection
↓
filling
↓
packaging

Every interface changes the risk.

Every transfer changes the product environment.

Every piece of equipment must therefore understand the process that precedes it and follows it.

Why Proc-X for Pharmaceutical Processing?

Because the most difficult pharmaceutical projects rarely belong to only one equipment category.

They cross technologies.

A powder may need:

AIS dosing + DP milling + QuantumX granulation + QuantumX vacuum drying + DP final sizing + InspeX verification + PreciXion packaging.

A liquid formulation may require:

AIS ingredient dosing + EmulXion high-shear preparation + high-pressure homogenization + thermal control + PreciXion filling.

Proc-X can see the process across those boundaries.

Specialist Technologies. One Process Partner.

The value of the Proc-X model is not simply having a broad product catalogue.

It is the ability to assign the appropriate technology to each unit operation while maintaining one process-engineering framework around the project.

The pharmaceutical customer gets:

specialized technology where specialization matters
integration where interfaces matter
documentation where qualification matters.

Engineering Before Equipment

We do not want the pharmaceutical conversation to begin with:

“What litre mixer do you want?”

We want it to begin with:

Then we select the equipment.

One Point of Accountability

A pharmaceutical process already involves coordination between Quality, Engineering, Production, Validation, EHS, Maintenance, R&D and Operations.

Proc-X is designed to reduce the additional burden of coordinating disconnected process-equipment vendors where the project benefits from integrated scope.

The goal is:

while preserving the specialist expertise required at each unit operation.

From Laboratory Development to Production

Many pharmaceutical processes begin small.

A customer may first need:

Once the process is understood, the system can be scaled toward production.

Scale-up should preserve the relevant process physics—not simply multiply vessel volume.

That may mean preserving relationships involving specific energy, tip speed, classifier behaviour, heat-transfer area, pressure, residence time or material loading.

Confidence Comes From Defining the Process

The strongest pharmaceutical equipment project is not the one with the longest specification sheet.

It is the one where the customer and supplier agree on:

That is where Proc-X intends to create value.

ONE INTEGRATED PROCESS

Raw Material to Documented Manufacturing System.

Proc-X integrates the process. From raw material to controlled pharmaceutical intermediate—and from process equipment to documented manufacturing system.

Talk to a Pharmaceutical Process Engineer →

Proc-X Manufacturing Group Inc. — Built to Process the Future.

TALK TO A PHARMACEUTICAL PROCESS ENGINEER

Discuss Your Pharmaceutical Application

Whether you are developing a new pharmaceutical process, scaling from R&D, replacing an existing machine, solving a difficult milling problem, automating ingredient additions, reducing material transfers, adding vacuum drying, developing a nano-emulsion, improving containment or integrating a complete manufacturing line, Proc-X can help define the equipment architecture around the process.

Request a Pharmaceutical Processing Proposal. Submit your URS or process requirements, and talk to a Proc-X process engineer about IQ / OQ / PQ requirements or a milling / process trial.